Oncology Insights Grant Program

They’re proud to recognize excellence in oncology research with tailored grant funding to support your continued discovery. As part of their Oncology Insights Grant Program, four researchers will be awarded an oncology-focused grant to use towards a service with GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences – including gene synthesis, precision antibody discovery using machine learning, next generation sequencing (NGS), and Olink proteomics.

Oncology Grants

• One grant towards a Gene Synthesis oncology application
  • Traditional molecular cloning methods are often complex. Gene synthesis provides an efficient method to quickly generate constructs for exploration of cancer mechanisms in vitro, while also providing precise sequence vectors for therapeutic development. Leveraging gene synthesis in your oncology research can enable you to efficiently characterize the effects of genomic mutations on the mechanisms of cellular functions.
• One grant towards a Precision Antibody Discovery oncology application
  • Selecting the right antibody leads from a large upstream pool with favorable downstream development characteristics the first time around is essential for successful, rapid therapeutic development. Combining NGS, machine learning bioinformatics, and recombinant antibody production into a singular workflow, their Precision Antibody Discovery service empowers you to rapidly discover diverse leads that you would otherwise miss with traditional screening technologies and processes– uncovering 5-10X more leads than low-throughput approaches.
• One grant towards an NGS oncology application
  • Cancer researchers can use whole genome, exome, and targeted amplicon next generation sequencing (NGS) approaches to characterize cancer-associated mutations and other biomarkers. Leveraging the latest long-read and short-read technology, GENEWIZ Next Generation Sequencing can help you gain a wider perspective and understanding of your research with comprehensive genomic coverage.
• One grant towards an Olink Proteomics oncology application
  • Olink Proteomics enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts to provide an in-depth understanding of disease and drug response. Using protein biomarker detection with Olink Proteomics, clinical trial researchers can identify known cancer biomarkers within a patient population to accurately identify subsets of the population with increased sensitivity to the therapeutic being tested.

Funding Information

• One award consists of a $5,000 value (or its local currency equivalent) toward a single order towards a GENEWIZ Gene Synthesis oncology application (no assay type restrictions).
• A second award consists of a $10,000 credit (or its local currency equivalent) toward a single order using the newly introduced GENEWIZ Precision Antibody Discovery (PAD) service.
• A third award of $5,000 (or its local currency equivalent) is to be allocated towards a single order using GENEWIZ Next Generation Sequencing in an oncology-related application.
• The fourth and final award of $5,000 (or its local currency equivalent) is to be used for a single order using GENEWIZ Olink Proteomics services offered through GENEWIZ from Azenta Life Sciences.
• All awarded amounts will be made available in the form of an account credit. Any unused credit will be forfeited and cannot be transferred to another project.​

Eligibility Criteria

• Participation in the GENEWIZ Oncology Insights 2024 Grant Program is open to individuals professionally engaged in laboratory-based scientific research and have attained at least the age of majority in their jurisdiction of residence (entrants must, in any event, be at least 18 years of age).

Ineligibility Criteria

• Employees, officers, directors, agents, representatives and independent contractors of the Sponsors, its subsidiaries, or affiliated companies, together with their immediate family members and members of the same households (whether related or not) are not eligible to participate.
• Also ineligible are
  • residents of Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, Russia, or any country subject to U.S. embargo;
  • any persons (including businesses, research institutions, government and private organizations, individuals, and other types of legal persons) on the U.S. government’s Denied Persons List, Specially Designated Nationals list, Entity List, Unverified List or any other similar list maintained by the U.S. government or any other government to whose laws the Sponsors, its subsidiaries or affiliated companies, the Grant Program or such person is subject, and all individuals employed thereby or otherwise associated therewith; and
  • any persons for whom it would be illegal to participate in or win the Grant Program, or with or to whom it would be illegal for the Sponsors to interact or award the prize as contemplated herein. The Grant Program is subject to all applicable laws and regulations, and is void where prohibited or where registration, bonding or language translation is required.

For more information, visit Azenta Life Sciences.